ORIGINAL ARTICLE

Serum uric acid and the risk of respiratory disease: a population-based cohort study

Laura J Horsfall, Irwin Nazareth, Irene Petersen

ABSTRACT

Introduction Uric acid is the most abundant molecule with antioxidant properties found in human blood serum. We examined the relationship between serum uric acid and the incidence of respiratory disease including any effect modification by smoking status.

Methods A cohort with serum uric acid measured between 1 January 2000 and 31 December 2012 was extracted from The Health Improvement Network primary care research database. New diagnoses of COPD and lung cancer were ascertained based on diagnostic codes entered into the medical records.

Results During 1 002 496 person years (PYs) of follow-up, there were 3901 COPD diagnoses and 1015 cases of lung cancer. After multivariable adjustment, strong interactions with smoking status were detected (p<0.001) for both outcomes with significant negative relationships between serum uric acid and respiratory disease for current smokers but no strong relationships for never-smokers or ex-smokers. The relationships were strongest for lung cancer in heavy smokers (≥20 cigarettes per day) with predicted incidence rates 97 per 10 000 PYs (95% CI 68 to 126) in the lowest serum uric acid quintile (100–250 μmol/L) compared with a predicted 28 per 10 000 PYs (95% CI 14 to 41) in the highest quintile (438–700 μmol/L).

Conclusions Low levels of serum uric acid are associated with higher rates of COPD and lung cancer in current smokers after accounting for conventional risk factors.

INTRODUCTION

Animal cells require adenine and guanine based purine compounds for survival. An unusual feature of hominoids (apes and humans) is that the catabolism of purines ends with uric acid whereas in most other mammals uric acid is converted to urea and allantoin prior to excretion in urine. The conversion (oxidation) of uric acid to urea is mediated by the hepatic enzyme uricase, which is absent in hominoids due to loss of function mutations in the uricase gene.1 As a consequence uric acid levels in human blood are around 50 times higher compared with non-primate mammals.2 The fact that repression or complete loss of uricase activity has occurred more than once during primate evolution, together with some usual features of the metabolic handling of uric acid, has led to speculation that raised levels may exert some kind of physiological benefit.

Accumulative damage to lipids, proteins and DNA by reactive oxygen species is the major mechanism underlying the free radical theory of aging and variation in levels of systemic serum antioxidants due to genetic and environmental influences, may have an important role susceptibility to a range of age-related diseases. Laboratory studies have identified powerful antioxidant properties for serum uric acid and with an average concentration of 300 μmol/L (5 mg/dL) it is the most abundant free radical ‘scavenger’ found in human blood.3 4 Estimates suggest 50% of human blood antioxidant capacity is due to the action of uric acid.5 The antioxidant properties of raised serum uric acid have been hypothesised to explain the low cancer rates and longevity in hominids relative to other mammals.6

The respiratory system is exposed to high levels or reactive oxygen species from industrial pollution, indoor fires, cigarette smoke and recurrent infections. Thus levels of serum antioxidants such as uric acid may have a particularly important role in susceptibility to respiratory disease. Furthermore, uric acid derived from serum is found at high concentration in the human epithelial lining fluid of the upper and lower respiratory tracts and appears to provide an important first-line defence against environmental oxidants.7 8 Serum uric acid is frequently measured in the primary care setting to diagnose gout, assess renal function and monitor drug response. However, the relationship with respiratory disease is not well characterised.

Key messages

What is the key question?

► Is there a relationship between serum uric acid, purported to be a major physiological antioxidant, and respiratory disease and does this differ according to smoking status?

What is the bottom line?

► After multivariable adjustment, strong interactions with smoking status were detected with significant negative relationships between serum uric acid and respiratory disease for current smokers but no strong relationships for never-smokers or ex-smokers.

Why read on?

► This is the first study to report higher rates of respiratory disease in people with low serum uric acid and the results suggest serum uric acid, a relatively cheap and routine test, could have some value in risk stratification within current smokers.
The aim of this study was to examine the relationship between serum uric acid and respiratory disease, specifically COPD and lung cancer. Antioxidant capacity may have a more important role in people exposed to high levels of reactive oxygen species and thus we tested for interactions with smoking status.

METHODS
Data source
Most general practitioners (GPs) in the UK record patient data electronically and some of these practices opt to provide these data for clinical and epidemiological research. The Health Improvement Network (THIN) primary care database currently holds anonymised longitudinal data on over 11 million patients registered with more than 500 practices, which represents around 6% of the UK population (http://csdmruk.cegedim.com). Information on diagnoses, symptoms and referrals to secondary care are electronically recorded using Read codes, a hierarchical coding system. All drug prescriptions as well as records of height, weight, blood pressure, smoking status and laboratory test results are entered onto the computer system. The database includes information of social deprivation (quintiles of Townsend score) based on owner-occupation, overcrowding, car ownership and unemployment levels derived from UK census data and linked to the patient’s postcode. A quintile score of local particle pollution levels is also provided. THIN data is representative of the UK general practice population in terms of demographics and consultation behaviour and electronically recorded diagnoses are accurate compared with other reliable sources.

Smoking levels in THIN data are similar to those reported in anonymous surveys.

The THIN scheme of providing anonymised patient data to researchers was approved by the National Health Service South-East Multi-centre Research Ethics Committee and the University College London Scientific Review Committee approved the present study.

Study population
A cohort of patients (≥30 years and <100 years of age) with a serum uric acid level recorded between 1 January 2000 and 31 December 2012 in standard international μmol/L units were extracted from THIN. Measurements were included if they were taken after the practice had achieved acceptable mortality recording and computer usage. This was to exclude earlier time periods when practices were not fully computerised. Patients were followed from the date of the first uric acid test until they have the event of interest, died, transferred to a different GP practice, or the study period ended (31 December 2012). Patients with raised uric acid due to chronic kidney disease were excluded.

Exposure
Serum uric acid levels are highly heritable and repeated measures in the same individual are fairly stable (intraclass correlation coefficient (ICC) 0.8). Therefore we extracted the earliest recorded measure and assumed this would broadly approximate exposure levels over time. The ICC for THIN patients was checked using a subset with more than two measures recorded in the same month. Based on the observed frequency distributions, we selected 100–700 μmol/L (1.7–11.8 mg/dL) as the range for this study (see online supplementary figure S1).

Outcomes
Lists of diagnostic Read codes for COPD and lung cancer were developed using a published methodology. Events were identified based on diagnoses in the patients’ record or as a cause of death. Disease events were considered incident if they were recorded at least 6 months after GP practice registration. For each analysis, patients with the diagnosis of interest recorded within 3 months of the uric acid test were excluded to help limit any reverse causation.

Covariates
Using the date of the uric acid test as the baseline, other variables extracted as potential confounders (or effect modifiers in the case of smoking) included gender, age, social deprivation, particle pollution, calendar year, smoking status (never, ex, light-moderate (1–19 cigarettes per day), heavy (≥20 cigarettes per day)), alcohol drinker (non, ex, current), blood pressure (systolic and diastolic), height, weight and non-European ethnicity. For covariates with multiple measurements, the value recorded closest to but prior to or on the date of the uric acid test (baseline) was selected. In total, 231 796 patients met the inclusion criteria and the majority had data on height, weight, smoking status and alcohol consumption recorded just prior to the uric acid test result. The 11% of patients with any missing data on height or weight (n=15 457), smoking or alcohol (n=10 883) and social deprivation (n=7231) were excluded from the cohort. Other variables including comorbidity, various drug prescriptions and creatinine levels as a measure of renal function were extracted and adjusted for in a supportive analysis (see online supplementary information).

Statistical analysis
Multivariable mixed Poisson regression was used to examine the relationship between serum uric acid levels and the clinical events of interest and to calculate adjusted incidence rate ratios (IRRs). Poisson models are appropriate for the analysis of person-time data when events are rare and goodness of fit to the Poisson model was checked using the deviance statistic. Serum uric acid and all continuous covariates were included in the regression models without categorisation. The GP practice was included in all models as a random effect to account for any data clustering. Multiplicative interactions between smoking and uric acid level were investigated by including the appropriate interaction terms in the regression model. Overall significance for categorical variables and interaction terms between uric acid and smoking status were tested using Wald tests. To help visualise interaction effects, regression model predictions were used to calculate the incidence rates across smoking categories for fixed values of serum uric acid assuming average values for the remaining covariates.

A p value of <0.05 was considered statistically significant (two-tailed) and all analyses were done using Stata V12.

All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

RESULTS
In total 205 484 patients (52% men) were included in the cohort with a median follow-up of 5 years from the date of the serum uric acid test (IQR: 2–7 years). During follow-up, 16 803 (8%) patients died and 31 219 (15%) transferred to different GP practices. The variables showing the strongest trends across uric acid quintiles were gender, age, weight and smoking status.
The ICC for patients with two uric acid tests in the same month was similar to the literature at 0.86. Only 2.6% of the variation in serum uric acid was explained by GP practice level variables suggesting the measurement methods are similar across UK laboratories.

During 1,002,496 person years (PYs) of follow-up, there were 3,901 COPD diagnoses and 1,015 cases of lung cancer (table 1). The crude disease incidence rates tended to increase across serum uric acid quintiles (table 1). After adjusting for potential confounders, each 100 μmol/L increase in serum uric acid was associated with a statistically non-significant 2% decrease in the incidence of COPD (IRR 0.98 (95% CI 0.94 to 1.01)) and a 5% decrease in the incidence of lung cancer (IRR 0.95 (95% CI 0.89 to 1.01)). However, interaction terms between uric acid level and smoking status were statistically significant for COPD (p<0.001) and lung cancer (p<0.001) (table 2). A stratified analysis showed negative relationships between uric acid and disease incidence in smokers, particularly for lung cancer.

Table 1: Overall cohort characteristics for variables used in the primary analyses and across quintile categories of serum uric acid (row percentages)

<table>
<thead>
<tr>
<th>Serum uric acid quintile (μmol/L)*</th>
<th>Overall</th>
<th>100–250</th>
<th>251–307</th>
<th>308–360</th>
<th>361–437</th>
<th>438–700</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>107,727 (52)</td>
<td>7111 (7)</td>
<td>14,634 (14)</td>
<td>23,306 (22)</td>
<td>29,988 (28)</td>
<td>32,688 (30)</td>
</tr>
<tr>
<td>Women</td>
<td>97,757 (48)</td>
<td>35,324 (36)</td>
<td>25,240 (26)</td>
<td>17,967 (18)</td>
<td>10,878 (11)</td>
<td>8348 (9)</td>
</tr>
<tr>
<td>Age, years</td>
<td>58.2 (14.4)</td>
<td>54.5 (14.6)</td>
<td>57.6 (14.2)</td>
<td>58.9 (13.8)</td>
<td>59.7 (13.8)</td>
<td>60.4 (14.6)</td>
</tr>
<tr>
<td>Height, cm</td>
<td>168 (10)</td>
<td>164.2 (8.3)</td>
<td>166.8 (9.6)</td>
<td>169.4 (10)</td>
<td>171.8 (9.6)</td>
<td>172.6 (9.5)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>79.7 (17.6)</td>
<td>69 (14.4)</td>
<td>75.8 (16)</td>
<td>81 (16.4)</td>
<td>85.3 (16.5)</td>
<td>88.1 (17.4)</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>80.1 (10.0)</td>
<td>77.5 (9.9)</td>
<td>79.5 (9.8)</td>
<td>80.5 (9.9)</td>
<td>81.4 (9.9)</td>
<td>81.5 (10.2)</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>135.4 (17.9)</td>
<td>129.7 (18.2)</td>
<td>134.1 (17.8)</td>
<td>136.5 (17.5)</td>
<td>138.1 (17.2)</td>
<td>138.7 (17.1)</td>
</tr>
</tbody>
</table>

Table 2: Adjusted incidence rate ratios (IRRs) of lung cancer and COPD as a function of 100 μmol/L (1.68 mg/dL) serum uric acid levels and including an interaction with smoking status

<table>
<thead>
<tr>
<th>Lung cancer</th>
<th>COPD</th>
<th>Adjusted IRRs*</th>
<th>(95% CI)</th>
<th>p Value</th>
<th>Adjusted IRRs*</th>
<th>(95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smoker</td>
<td>1.00</td>
<td>(Reference)</td>
<td></td>
<td></td>
<td>1.00</td>
<td>(Reference)</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>3.49</td>
<td>(1.70 to 7.16)</td>
<td>2.97</td>
<td>2.17 to 4.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Light-moderate (1–19 per day)</td>
<td>19.54</td>
<td>(8.93 to 42.79)</td>
<td>12.89</td>
<td>9.06 to 18.35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heavy (≥20 per day)</td>
<td>58.85</td>
<td>(25.27 to 137.08)</td>
<td>&lt;0.001</td>
<td>19.69</td>
<td>(13.29 to 29.17)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Serum uric acid (per 100 μmol/L)†</td>
<td>1.00</td>
<td>(0.84 to 1.19)</td>
<td>NS</td>
<td>0.96 to 1.11</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-smoker X uric acid</td>
<td>1.00</td>
<td>(Reference)</td>
<td></td>
<td></td>
<td>1.00</td>
<td>(Reference)</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker X uric acid</td>
<td>1.04</td>
<td>(0.86 to 1.26)</td>
<td>1.01</td>
<td>(0.93 to 1.10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Light-moderate smoker X uric acid</td>
<td>0.87</td>
<td>(0.70 to 1.09)</td>
<td>0.86</td>
<td>(0.78 to 0.96)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heavy smoker X uric acid</td>
<td>0.72</td>
<td>(0.56 to 0.92)</td>
<td>&lt;0.001</td>
<td>0.85</td>
<td>(0.76 to 0.95)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Wald tests were used to calculate p values for categorical variables and interaction terms
*Adjusted for age, sex, social deprivation, year of uric acid test, smoking status, alcohol, height, weight, blood pressure, non-European ethnicity and particle pollution.
†Conversion factor: μmol/L×0.01 681 mg/dL.
NS, non-significant.
Table 3 Crude incidence rates and adjusted incidence rate ratios (IRRs) of lung cancer and COPD as a function of 100 μmol/L (1.68 mg/dL) serum uric acid levels stratified on smoking status

<table>
<thead>
<tr>
<th>Lung cancer</th>
<th>Events/PYs per 10 000</th>
<th>Crude incidence rate (95% CI)</th>
<th>Adjusted IRRs* (95% CI) per 100 μmol/L increase in uric acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smoker</td>
<td>112/43.7</td>
<td>2.6 (2.1 to 3.1)</td>
<td>1.04 (0.85 to 1.26)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>531/35.4</td>
<td>15.0 (13.8 to 16.3)</td>
<td>1.04 (0.96 to 1.14)</td>
</tr>
<tr>
<td>Light-moderate</td>
<td>226/8.9</td>
<td>25.4 (22.3 to 29.0)</td>
<td>0.91 (0.78 to 1.05)</td>
</tr>
<tr>
<td>Heavy</td>
<td>146/4.5</td>
<td>32.2 (27.3 to 37.8)</td>
<td>0.72 (0.59 to 0.87)</td>
</tr>
</tbody>
</table>

COPD

| Non-smoker  | 643/41.1              | 15.7 (14.5 to 16.9)          | 1.03 (0.94 to 1.12)                                         |
| Ex-smoker   | 1894/31.2             | 60.7 (58.0 to 63.5)          | 1.03 (0.99 to 1.08)                                         |
| Light-moderate | 822/7.6        | 108 (101 to 116)            | 0.88 (0.81 to 0.95)                                         |
| Heavy       | 542/3.9              | 140 (129 to 153)            | 0.91 (0.83 to 1.00)                                         |

*Adjusted for age, sex, social deprivation, year of uric acid test, alcohol, height, weight, blood pressure, non-European ethnicity and particle pollution.

Wald tests were used to calculate p values for categorical variables and interaction terms.

Table 4 Adjusted incidence predictions for lung cancer and COPD as a function of serum uric acid levels showing an interaction with smoking status

<table>
<thead>
<tr>
<th>Serum uric acid quintiles (μmol/L)</th>
<th>100–250 n=42 435</th>
<th>251–307 n=39 874</th>
<th>308–360 n=41 273</th>
<th>361–437 n=40 866</th>
<th>438–700 n=41 036</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predicted incidence of lung cancer per 10 000 PYs (95% CI)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-smoker</td>
<td>3.0 (1.9 to 4.1)</td>
<td>3.0 (2.3 to 3.7)</td>
<td>3.0 (2.4 to 3.6)</td>
<td>3.0 (2.4 to 3.7)</td>
<td>3.1 (1.7 to 4.4)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>11.2 (9.0 to 13.4)</td>
<td>11.8 (10.4 to 13.3)</td>
<td>12.2 (10.9 to 13.4)</td>
<td>12.6 (11.4 to 13.9)</td>
<td>13.8 (11.3 to 16.4)</td>
</tr>
<tr>
<td>Light-moderate</td>
<td>45.9 (34.2 to 57.7)</td>
<td>40.2 (33.7 to 46.7)</td>
<td>37.5 (32.0 to 43.0)</td>
<td>34.5 (28.5 to 40.5)</td>
<td>27.8 (18.0 to 37.5)</td>
</tr>
<tr>
<td>Heavy</td>
<td>97.0 (67.8 to 126.3)</td>
<td>69.6 (56.1 to 83.1)</td>
<td>58.4 (47.3 to 69.4)</td>
<td>47.4 (36.0 to 58.8)</td>
<td>27.5 (14.2 to 40.9)</td>
</tr>
<tr>
<td>Predicted incidence of COPD per 10 000 PYs (95% CI)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-smoker</td>
<td>16.6 (14.0 to 19.3)</td>
<td>17.1 (15.3 to 18.9)</td>
<td>17.4 (15.8 to 18.9)</td>
<td>17.7 (15.9 to 19.4)</td>
<td>18.5 (15.0 to 22.0)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>49.5 (44.0 to 54.9)</td>
<td>51.4 (47.4 to 55.4)</td>
<td>52.4 (48.9 to 56.0)</td>
<td>53.7 (50.1 to 57.3)</td>
<td>57.2 (50.9 to 63.4)</td>
</tr>
<tr>
<td>Light-moderate</td>
<td>167.3 (144.1 to 190.5)</td>
<td>147.1 (133.3 to 160.8)</td>
<td>137.4 (125.3 to 149.4)</td>
<td>126.7 (113.8 to 139.6)</td>
<td>102.6 (82.7 to 122.6)</td>
</tr>
<tr>
<td>Heavy</td>
<td>247.7 (206.6 to 288.8)</td>
<td>213.2 (189.6 to 236.7)</td>
<td>196.9 (176.5 to 217.4)</td>
<td>179.3 (157.3 to 201.3)</td>
<td>140.3 (106.8 to 173.8)</td>
</tr>
</tbody>
</table>

The median (middle) value of serum uric acid within each quintile was used as the fixed value for the prediction.

*Adjusted for age, sex, social deprivation, year of uric acid test, alcohol, height, weight, blood pressure, non-European ethnicity and particle pollution.

PYs, person years.
of 78,850 Austrian men. This study reported a weak J-shaped relationship with no evidence of an interaction with smoking status. Around 70% of the Austrian cohort were never smokers (the proportion of current smokers not specifically reported) and the number of events were lower (n=883) and thus it is possible the study lacked statistical power to detect interactions with smoking status. In the absence of a biological mechanism and based on other observations, the authors of the Austrian study speculate that the positive relationships with respiratory and other cancers examined are due to serum uric acid acting as a proxy for other unmeasured lifestyle variables.

The main strength of the present study is the large sample size that enabled us to detect the interactions between serum uric acid and smoking status. The longitudinal nature of the data meant we could examine the relationship with overall disease incidence rates and limit any potential for reverse causation. The study used routine medical data from the general population and therefore smokers and people from more socially deprived areas were well represented, which is not always the case for cohorts with active recruitment (‘healthy cohort effect’). However, differential confounding or bias may occur across smoking strata and either dilute or overestimate the relationships. Low serum uric acid could partially reflect length, intensity and timing of exposure to smoke oxidants but this is difficult to measure without lifetime follow-up data although most adult smokers in the UK adopt the habit in adolescence. We adjusted for smoking intensity as a continuous covariate in a supportive analysis, however the negative relationships in smokers could still reflect some level of self-reported underestimation of smoking intensity. In contrast with many other cancers, a number of studies have reported that raised body mass index (BMI) is associated with a lower risk of smoking-related cancers even after careful adjustment for smoking duration/intensity and reverse causation. Furthermore, a casual relationship between raised BMI due to increased energy intake and reduced risk of lung cancer was suggested by an analysis using ‘Mendelian randomization’. A clear biological mechanism to potentially explain these associations has not been proposed. However, if uric acid does function as a major serum antioxidant, higher energy intake causing raised levels may contribute to a lower risk of smoking-related cancers. Alternatively serum uric acid may be capturing unrecorded information on adiposity and energy intake in our cohort. This information can be hard to measure reliably in the primary care setting and serum uric acid may still have a role in identifying high-risk smokers regardless of causality.

It is also plausible that the associations were diluted across smoking strata due to residual confounding by unmeasured lifestyle factors as suggested for cardiometabolic diseases. For example, those in the upper end of the uric acid distribution may have lower levels of physical activity due to gout and poorer quality diets low in exogenous antioxidants. Surveillance bias could be a problem and dilute true associations if GPs are more likely to further investigate and diagnose conditions in patients with raised serum uric acid due to concerns over renal disease. However, this is less of an issue for the ‘harder’ outcome of lung cancer. We only used a single measure of uric acid as the exposure and thus regression dilution bias may have attenuated the relationships with respiratory outcomes. Patients were selected from THIN with a serum uric measure and thus risk factors for gout such as being overweight may be more common in this cohort relative to the UK population limiting the generalisability of the findings. Finally, the UK is over 90% white European and therefore the results may not be generalisable to other ethnic groups.

Lung cancer is the most common cause of cancer death globally with late diagnosis a major contributor to this high mortality burden. In the UK for example, just 15% of lung cancers are diagnosed at an early stage when treatment is most effective (http://www.gov.uk/phe). A recent clinical trial in the USA gained international attention when it reported that annual CT chest screening for high-risk smokers reduced lung cancer mortality by 20%. However, even within this high-risk group,
disease susceptibility was highly variable and further risk stratification is desirable for cost-effectiveness and to improve social acceptability of a screening procedure with a high rate of false positive results. The strength of the associations in current smokers in the present paper suggests a role for uric acid in improving risk stratification irrespective of causal relationships. Given the low cost and accessibility of this assay in the primary care setting, this is an important area for further research.

Various hypotheses have emerged over the past 50 years to explain the inactivation of uricase during primavite escalation. These are increased intellectual ability, maintenance of blood pressure in times of low salt/purine availability, and longevity due to protection against oxidative stress. Our results although consistent with the latter do not argue against these other hypotheses. If the relationships found in the presents study are real and serum uric acid is an important antioxidant, drugs that lower levels may not be appropriate for smokers due to the increased risk of developing respiratory diseases. Establishing antioxidant causality could be achieved through randomised controlled trials of uric acid administration. For example, two randomised double-blind placebo-controlled trials reported that administration of uric acid improves endothelial function and increases antioxidant capacity. There is an urgent need for larger studies of this nature that consider the potential benefits and harms (ie, increased risk of gout).

Current smokers with low serum uric acid levels have substantially higher rates of respiratory diseases compared with smokers with raised levels after accounting for conventional risk factors. The results of this study lend support to the hypothesis that uric acid functions as a serum antioxidant but causality remains to be proven. Whether serum uric acid has a clinically useful role or not will await the results of larger studies of this nature that consider the potential benefits and harms (ie, increased risk of gout).

References

Serum uric acid and the risk of respiratory disease: a population-based cohort study

Laura J Horsfall, Irwin Nazareth and Irene Petersen

Thorax 2014 69: 1021-1026 originally published online June 5, 2014
doi: 10.1136/thoraxjnl-2014-205271

Updated information and services can be found at:
http://thorax.bmj.com/content/69/11/1021

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2014/06/05/thoraxjnl-2014-205271.1.DC1

References
This article cites 33 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/69/11/1021#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (127)
Open access (251)
Health education (1223)
Smoking (1037)
Tobacco use (1039)
Health effects of tobacco use (211)
Lung cancer (oncology) (670)
Lung cancer (respiratory medicine) (670)
Lung neoplasms (608)
Epidemiologic studies (1829)
General practice / family medicine (339)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/